To include your compound in the COVID-19 Resource Center, submit it here.

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint
VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs. three doses of Engerix-B from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at day 196 in the Phase III PROTECT trial. The

Read the full 531 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers